Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study

[1] Shimamoto K(2014)The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014) Hypertens Res 37 253-390

[2] Ando K(2004)Overweight, ethnicity, and the prevalence of hypertension in school-aged children Pediatrics 113 475-482

[3] Fujita T(2010)Hypertension in children and adolescents: epidemiology and natural history Pediatr Nephrol 25 1219-1224

[4] Sorof JM(2012)Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study Hypertens Res 35 552-558

[5] Lai D(2017)Azilsartan in patients with mild to moderate hypertension using clinic and ambulatory blood pressure measurements J Clin Hypertens 19 82-89

[6] Turner J(2008)Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years J Clin Hypertens (Greenwich) 10 743-750

[7] Poffenbarger T(2011)Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension J Clin Hypertens (Greenwich) 13 357-365

[8] Portman RJ(2012)Azilsartan medoxomil: a review of its use in hypertension Clin Drug Investig 32 621-639

[9] Falkner B(2013)Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment Clin Pharmacokinet 52 347-358

[10] Rakugi H(2012)Single-center phase I study of the single- and multiple-dose pharmacokinetics and safety of azilsartan medoxomil (AZL-M) in hepatic impairment (abstract no. PII-99) Clin Pharmacol Ther 91 S89-1589

[1] Shimamoto K(2014)The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014) Hypertens Res 37 253-390

[2] Ando K(2004)Overweight, ethnicity, and the prevalence of hypertension in school-aged children Pediatrics 113 475-482

[3] Fujita T(2010)Hypertension in children and adolescents: epidemiology and natural history Pediatr Nephrol 25 1219-1224

[4] Sorof JM(2012)Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study Hypertens Res 35 552-558

[5] Lai D(2017)Azilsartan in patients with mild to moderate hypertension using clinic and ambulatory blood pressure measurements J Clin Hypertens 19 82-89

[6] Turner J(2008)Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years J Clin Hypertens (Greenwich) 10 743-750

[7] Poffenbarger T(2011)Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension J Clin Hypertens (Greenwich) 13 357-365

[8] Portman RJ(2012)Azilsartan medoxomil: a review of its use in hypertension Clin Drug Investig 32 621-639

[9] Falkner B(2013)Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment Clin Pharmacokinet 52 347-358

[10] Rakugi H(2012)Single-center phase I study of the single- and multiple-dose pharmacokinetics and safety of azilsartan medoxomil (AZL-M) in hepatic impairment (abstract no. PII-99) Clin Pharmacol Ther 91 S89-1589